Maëlle Duffey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maëlle Duffey has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Didier Leroy
MMV Medicines for Malaria Venture, Geneva, Switzerland
5 shared publications - Benjamin Blasco
Global Antibiotic Research & Development Partnership (GARDP), Chemin Camille-Vidart 15, 1202 Geneva, Switzerland
3 shared publications Christin Gumpp
University of Basel, Basel, Switzerland
3 shared publications- Matthias Rottmann
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute
3 shared publications - Artur Scherf
Institut Pasteur, Biology of Host-Parasite Interactions Unit, INSERM U1201, CNRS EMR9195, Paris, France
2 shared publications - Basil T. Thommen
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Communications Medicine
Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models
Background: The 8-aminoquinoline primaquine is used as a single low dose with antimalarial treatment to reduce malaria transmission. An alternative 8-aminoquinoline, tafenoquine has a substantially longer half-life and may therefore provide more sustained transmission-blocking activity, but direct comparisons with primaquine are limited. We compare the transmission-blocking activity and pharmacokinetics of these drugs in vivo. Methods: We assess primaquine dose response in Plasmodium berghei -infected mice and compare an equimolar dose of tafenoquine in a mouse-to-mosquito-to-mouse transmission model. We also assess both drugs against Plasmodium falciparum gametocytes in humanized immunodeficient mice using bioluminescence and microscopy, and measure plasma drug concentrations. Dose-response relationships are modeled using generalized linear and nonlinear regression, with appropriate statistical tests for transmission and parasite endpoints. Results: Here we show that primaquine produces stronger early transmission-blocking activity, reducing mosquito infection more effectively than tafenoquine 24 hours after treatment. In contrast, tafenoquine retains greater activity at later time points, coinciding with prolonged systemic exposure. Similar temporal differences are observed when the drugs are combined with the schizonticide sulphadiazine. In humanized mice, both drugs reduce gametocyte abundance in a dose-dependent manner, while tafenoquine shows sustained exposure for several days compared with the more rapid decline of parent primaquine. Conclusions: Primaquine and tafenoquine have distinct temporal transmission-blocking profiles in vivo. Sustained activity of tafenoquine is consistent with prolonged exposure rather than greater intrinsic potency. These findings are observed across multiple models, both in the absence or presence of a partner schizonticide and thus demonstrate a potential advantage of the utilization of tafenoquine when compared to primaquine.
- 10 November 2026
- Published by Springer Nature in Communications Medicine
Open AccessComparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models
Background: The 8-aminoquinoline primaquine is used as a single low dose with antimalarial treatment to reduce malaria transmission. An alternative 8-aminoquinoline, tafenoquine has a substantially longer half-life and may therefore provide more sustained transmission-blocking activity, but direct comparisons with primaquine are limited. We compare the transmission-blocking activity and pharmacokinetics of these drugs in vivo. Methods: We assess primaquine dose response in Plasmodium berghei -infected mice and compare an equimolar dose of tafenoquine in a mouse-to-mosquito-to-mouse transmission model. We also assess both drugs against Plasmodium falciparum gametocytes in humanized immunodeficient mice using bioluminescence and microscopy, and measure plasma drug concentrations. Dose-response relationships are modeled using generalized linear and nonlinear regression, with appropriate statistical tests for transmission and parasite endpoints. Results: Here we show that primaquine produces stronger early transmission-blocking activity, reducing mosquito infection more effectively than tafenoquine 24 hours after treatment. In contrast, tafenoquine retains greater activity at later time points, coinciding with prolonged systemic exposure. Similar temporal differences are observed when the drugs are combined with the schizonticide sulphadiazine. In humanized mice, both drugs reduce gametocyte abundance in a dose-dependent manner, while tafenoquine shows sustained exposure for several days compared with the more rapid decline of parent primaquine. Conclusions: Primaquine and tafenoquine have distinct temporal transmission-blocking profiles in vivo. Sustained activity of tafenoquine is consistent with prolonged exposure rather than greater intrinsic potency. These findings are observed across multiple models, both in the absence or presence of a partner schizonticide and thus demonstrate a potential advantage of the utilization of tafenoquine when compared to primaquine.
- Open Access
- 7 September 2026
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 51, 78-88
In vitro activity of flomoxef, fosfomycin, and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens
- 7 September 2026
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 51, 78-88
Open AccessIn vitro activity of flomoxef, fosfomycin, and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens
- Open Access
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2327
Mechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum
The emergence of multi-drug resistant Plasmodium falciparum underscores the urgent need for new antimalarial therapies. SC83288, a chemically distinct antimalarial compound, is highly effective against P. falciparum both in vivo and in vitro, including strains resistant to artemisinin and partner drugs. Here, we show that SC83288 disrupts blood-stage development by blocking DNA replication and arresting karyokinesis. We identify the parasite’s DNA and tRNA Asp methyltransferase PfDNMT2 as a primary molecular target, linking drug action to impaired epigenetic regulation, altered S-adenosylmethionine fluxes, and compensatory transcriptional responses. Resistance to SC83288 arises through mutations in the parasite’s SERCA-type Ca²⁺ ATPase PfATP6, which enable transport of the compound into the endoplasmic reticulum, away from its nuclear targets. This resistance mechanism carries a substantial fitness cost, limiting its potential for spread. Together, target validation, a unique resistance profile, and high fitness cost strengthen SC83288’s potential as a promising clinical development candidate for malaria treatment.
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2327
Open AccessMechanisms of PfDNMT2 inhibition and PfATP6-mediated resistance to the antimalarial candidate SC83288 in Plasmodium falciparum
The emergence of multi-drug resistant Plasmodium falciparum underscores the urgent need for new antimalarial therapies. SC83288, a chemically distinct antimalarial compound, is highly effective against P. falciparum both in vivo and in vitro, including strains resistant to artemisinin and partner drugs. Here, we show that SC83288 disrupts blood-stage development by blocking DNA replication and arresting karyokinesis. We identify the parasite’s DNA and tRNA Asp methyltransferase PfDNMT2 as a primary molecular target, linking drug action to impaired epigenetic regulation, altered S-adenosylmethionine fluxes, and compensatory transcriptional responses. Resistance to SC83288 arises through mutations in the parasite’s SERCA-type Ca²⁺ ATPase PfATP6, which enable transport of the compound into the endoplasmic reticulum, away from its nuclear targets. This resistance mechanism carries a substantial fitness cost, limiting its potential for spread. Together, target validation, a unique resistance profile, and high fitness cost strengthen SC83288’s potential as a promising clinical development candidate for malaria treatment.
- Open Access
- 25 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6884
An all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs
Elimination of malaria will require new drugs with potent activity against Plasmodium falciparum mature stage V gametocytes, the only stages infective to the mosquito vector. The identification and comprehensive validation of molecules active against these quiescent stages is difficult due to the specific biology of gametocytes, challenges linked to their cultivation in vitro and the lack of animal models suitable for evaluating the transmission-blocking potential of drug candidates in vivo. Here, we present a transmission-blocking drug discovery and development platform that builds on transgenic NF54/iGP1_RE9Hulg8 parasites engineered to conditionally produce large numbers of stage V gametocytes expressing a red-shifted firefly luciferase viability reporter. Besides developing a robust in vitro screening assay for the reliable identification of stage V gametocytocidal compounds, we also establish a preclinical in vivo malaria transmission model based on infecting female humanized NODscidIL2Rγnull mice with pure NF54/iGP1_RE9Hulg8 stage V gametocytes. Using whole animal bioluminescence imaging, we assess the in vivo gametocyte killing and clearance kinetics of antimalarial reference drugs and clinical drug candidates and identify markedly different pharmacodynamic response profiles. Finally, we combine this mouse model with mosquito feeding assays and thus firmly establish a valuable tool for the systematic in vivo evaluation of transmission-blocking drug efficacy.
- 25 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6884
Open AccessAn all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs
Elimination of malaria will require new drugs with potent activity against Plasmodium falciparum mature stage V gametocytes, the only stages infective to the mosquito vector. The identification and comprehensive validation of molecules active against these quiescent stages is difficult due to the specific biology of gametocytes, challenges linked to their cultivation in vitro and the lack of animal models suitable for evaluating the transmission-blocking potential of drug candidates in vivo. Here, we present a transmission-blocking drug discovery and development platform that builds on transgenic NF54/iGP1_RE9Hulg8 parasites engineered to conditionally produce large numbers of stage V gametocytes expressing a red-shifted firefly luciferase viability reporter. Besides developing a robust in vitro screening assay for the reliable identification of stage V gametocytocidal compounds, we also establish a preclinical in vivo malaria transmission model based on infecting female humanized NODscidIL2Rγnull mice with pure NF54/iGP1_RE9Hulg8 stage V gametocytes. Using whole animal bioluminescence imaging, we assess the in vivo gametocyte killing and clearance kinetics of antimalarial reference drugs and clinical drug candidates and identify markedly different pharmacodynamic response profiles. Finally, we combine this mouse model with mosquito feeding assays and thus firmly establish a valuable tool for the systematic in vivo evaluation of transmission-blocking drug efficacy.
- Open Access
An all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs
Elimination and eradication of malaria will depend on new drugs with potent activity against Plasmodium falciparum mature stage V gametocytes, the only stages able to infect the mosquito vector for onward parasite transmission. The identification of molecules active against these quiescent stages is difficult due to the specific biology of gametocyte maturation and challenges linked to their cultivation in vitro . Furthermore, the antimalarial drug development pipeline lacks a suitable animal model for evaluating the transmission-blocking potential of promising lead compounds and preclinical and clinical drug candidates in vivo . Here, we established a transmission-blocking drug discovery and development platform based on transgenic P. falciparum parasites engineered to produce large numbers of pure stage V gametocytes expressing a red-shifted firefly luciferase as reporter for cellular viability. This NF54/iGP1_RE9H ulg8 line facilitated the development of a highly efficient and robust in vitro screening assay for the identification of stage V gametocytocidal compounds. Importantly, by infecting humanized NODscidIL2Rγ null mice with pure NF54/iGP1_RE9H ulg8 stage V gametocytes, we also established a preclinical P. falciparum in vivo transmission model. Using whole animal bioluminescence imaging and quantification of gametocyte densities over a period of 14 days, we assessed the gametocyte killing and clearance kinetics in vivo of antimalarial reference drugs as well as five clinical drug candidates and identified markedly different pharmacodynamic response profiles. Furthermore, we successfully integrated this mouse model with mosquito feeding assays and thus firmly established a valuable tool for the systematic in vivo evaluation of gametocytocidal and transmission-blocking drug efficacy. One sentence summary: We applied robust new assays for gametocytocidal drug discovery and in vivo efficacy testing using a humanized mouse model for malaria transmission
Open AccessAn all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs
Elimination and eradication of malaria will depend on new drugs with potent activity against Plasmodium falciparum mature stage V gametocytes, the only stages able to infect the mosquito vector for onward parasite transmission. The identification of molecules active against these quiescent stages is difficult due to the specific biology of gametocyte maturation and challenges linked to their cultivation in vitro . Furthermore, the antimalarial drug development pipeline lacks a suitable animal model for evaluating the transmission-blocking potential of promising lead compounds and preclinical and clinical drug candidates in vivo . Here, we established a transmission-blocking drug discovery and development platform based on transgenic P. falciparum parasites engineered to produce large numbers of pure stage V gametocytes expressing a red-shifted firefly luciferase as reporter for cellular viability. This NF54/iGP1_RE9H ulg8 line facilitated the development of a highly efficient and robust in vitro screening assay for the identification of stage V gametocytocidal compounds. Importantly, by infecting humanized NODscidIL2Rγ null mice with pure NF54/iGP1_RE9H ulg8 stage V gametocytes, we also established a preclinical P. falciparum in vivo transmission model. Using whole animal bioluminescence imaging and quantification of gametocyte densities over a period of 14 days, we assessed the gametocyte killing and clearance kinetics in vivo of antimalarial reference drugs as well as five clinical drug candidates and identified markedly different pharmacodynamic response profiles. Furthermore, we successfully integrated this mouse model with mosquito feeding assays and thus firmly established a valuable tool for the systematic in vivo evaluation of gametocytocidal and transmission-blocking drug efficacy. One sentence summary: We applied robust new assays for gametocytocidal drug discovery and in vivo efficacy testing using a humanized mouse model for malaria transmission
- 15 May 2024
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 23 (6) , 461-479
Combating antimicrobial resistance in malaria, HIV and tuberculosis
Antimicrobial resistance poses a significant threat to the sustainability of effective treatments against the three most prevalent infectious diseases: malaria, human immunodeficiency virus (HIV) infection and tuberculosis. Therefore, there is an urgent need to develop novel drugs and treatment protocols capable of reducing the emergence of resistance and combating it when it does occur. In this Review, we present an overview of the status and underlying molecular mechanisms of drug resistance in these three diseases. We also discuss current strategies to address resistance during the research and development of next-generation therapies. These strategies vary depending on the infectious agent and the array of resistance mechanisms involved. Furthermore, we explore the potential for cross-fertilization of knowledge and technology among these diseases to create innovative approaches for minimizing drug resistance and advancing the discovery and development of new anti-infective treatments. In conclusion, we advocate for the implementation of well-defined strategies to effectively mitigate and manage resistance in all interventions against infectious diseases.
- 15 May 2024
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 23 (6) , 461-479
Combating antimicrobial resistance in malaria, HIV and tuberculosis
Antimicrobial resistance poses a significant threat to the sustainability of effective treatments against the three most prevalent infectious diseases: malaria, human immunodeficiency virus (HIV) infection and tuberculosis. Therefore, there is an urgent need to develop novel drugs and treatment protocols capable of reducing the emergence of resistance and combating it when it does occur. In this Review, we present an overview of the status and underlying molecular mechanisms of drug resistance in these three diseases. We also discuss current strategies to address resistance during the research and development of next-generation therapies. These strategies vary depending on the infectious agent and the array of resistance mechanisms involved. Furthermore, we explore the potential for cross-fertilization of knowledge and technology among these diseases to create innovative approaches for minimizing drug resistance and advancing the discovery and development of new anti-infective treatments. In conclusion, we advocate for the implementation of well-defined strategies to effectively mitigate and manage resistance in all interventions against infectious diseases.
- Top Cited PapersOpen Access
- 25 April 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (5) , 1458-1482
Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps
Efflux is a natural process found in all prokaryotic and eukaryotic cells that removes a diverse range of substrates from inside to outside. Many antibiotics are substrates of bacterial efflux pumps, and modifications to the structure or overexpression of efflux pumps are an important resistance mechanism utilized by many multidrug-resistant bacteria. Therefore, chemical inhibition of bacterial efflux to revitalize existing antibiotics has been considered a promising approach for antimicrobial chemotherapy over two decades, and various strategies have been employed. In this review, we provide an overview of bacterial multidrug resistance (MDR) efflux pumps, of which the resistance nodulation division (RND) efflux pumps are considered the most clinically relevant in Gram-negative bacteria, and describe over 50 efflux inhibitors that target such systems. Although numerous efflux inhibitors have been identified to date, none have progressed into clinical use because of formulation, toxicity, and pharmacokinetic issues or a narrow spectrum of inhibition. For these reasons, the development of efflux inhibitors has been considered a difficult and complex area of research, and few active preclinical studies on efflux inhibitors are in progress. However, recently developed tools, including but not limited to computational tools including molecular docking models, offer hope that further research on efflux inhibitors can be a platform for research and development of new bacterial efflux inhibitors.
- 25 April 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (5) , 1458-1482
Top Cited PapersOpen AccessExtending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps
Efflux is a natural process found in all prokaryotic and eukaryotic cells that removes a diverse range of substrates from inside to outside. Many antibiotics are substrates of bacterial efflux pumps, and modifications to the structure or overexpression of efflux pumps are an important resistance mechanism utilized by many multidrug-resistant bacteria. Therefore, chemical inhibition of bacterial efflux to revitalize existing antibiotics has been considered a promising approach for antimicrobial chemotherapy over two decades, and various strategies have been employed. In this review, we provide an overview of bacterial multidrug resistance (MDR) efflux pumps, of which the resistance nodulation division (RND) efflux pumps are considered the most clinically relevant in Gram-negative bacteria, and describe over 50 efflux inhibitors that target such systems. Although numerous efflux inhibitors have been identified to date, none have progressed into clinical use because of formulation, toxicity, and pharmacokinetic issues or a narrow spectrum of inhibition. For these reasons, the development of efflux inhibitors has been considered a difficult and complex area of research, and few active preclinical studies on efflux inhibitors are in progress. However, recently developed tools, including but not limited to computational tools including molecular docking models, offer hope that further research on efflux inhibitors can be a platform for research and development of new bacterial efflux inhibitors.
- Top Cited Papers
- 13 October 2023
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 22 (12) , 957-975
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections
Advances in areas that include genomics, systems biology, protein structure determination and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. The selection of a ‘good’ new target for direct-acting antibacterial compounds is the first decision, for which multiple criteria must be explored, integrated and re-evaluated as drug discovery programmes progress. Criteria include essentiality of the target for bacterial survival, its conservation across different strains of the same species, bacterial species and growth conditions (which determines the spectrum of activity of a potential antibiotic) and the level of homology with human genes (which influences the potential for selective inhibition). Additionally, a bacterial target should have the potential to bind to drug-like molecules, and its subcellular location will govern the need for inhibitors to penetrate one or two bacterial membranes, which is a key challenge in targeting Gram-negative bacteria. The risk of the emergence of target-based drug resistance for drugs with single targets also requires consideration. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and examples of cognate inhibitors, and highlights lessons learned from past drug discovery programmes.
- 13 October 2023
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 22 (12) , 957-975
Top Cited PapersUnrealized targets in the discovery of antibiotics for Gram-negative bacterial infections
Advances in areas that include genomics, systems biology, protein structure determination and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. The selection of a ‘good’ new target for direct-acting antibacterial compounds is the first decision, for which multiple criteria must be explored, integrated and re-evaluated as drug discovery programmes progress. Criteria include essentiality of the target for bacterial survival, its conservation across different strains of the same species, bacterial species and growth conditions (which determines the spectrum of activity of a potential antibiotic) and the level of homology with human genes (which influences the potential for selective inhibition). Additionally, a bacterial target should have the potential to bind to drug-like molecules, and its subcellular location will govern the need for inhibitors to penetrate one or two bacterial membranes, which is a key challenge in targeting Gram-negative bacteria. The risk of the emergence of target-based drug resistance for drugs with single targets also requires consideration. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and examples of cognate inhibitors, and highlights lessons learned from past drug discovery programmes.
- Open Access
- 23 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 163
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [3H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9%) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction.
- 23 January 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (2) , 163
Open AccessThe Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [3H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9%) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction.
- Open Access
- 21 July 2022
- Published by Elsevier in SLAS Discovery
- Vol. 27 (6) , 337-348
Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out
- 21 July 2022
- Published by Elsevier in SLAS Discovery
- Vol. 27 (6) , 337-348
Open AccessReplenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out